Genmab Email Format
Biotechnology ResearchHovedstaden, Denmark1001-5000 Employees
Genmab is an international biotechnology company focused on developing antibody medicines to improve outcomes for people with cancer and other serious diseases. The company is advancing a substantial late-stage clinical pipeline with wholly owned programs, seeking to deliver transformative medicines to patients. Headquartered in Copenhagen, Denmark, Genmab has a broad international footprint across North America, Europe, and the Asia Pacific region. Its primary customers are patients and clinicians seeking new cancer therapies, as well as health systems that support delivery of advanced treatments. In June 2026, Genmab reported data from studies of epcoritamab in first-line diffuse large B-cell lymphoma, noting high response rates in elderly patients.